Citations (85)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Serena Tonstad, Cynthia Arons, Hans Rollema, Ivan Berlin, Peter Hajek, Karl Fagerström, Charl Els, Thomas McRae & Cristina Russ. (2020) Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations. Current Medical Research and Opinion 36:5, pages 713-730.
Read now
Read now
Chloe J. Jordan & Zheng-Xiong Xi. (2018) Discovery and development of varenicline for smoking cessation. Expert Opinion on Drug Discovery 13:7, pages 671-683.
Read now
Read now
Michael V Burke, J Taylor Hays & Jon O Ebbert. (2016) Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence. Patient Preference and Adherence 10, pages 435-441.
Read now
Read now
Dan Xiao, Shuilian Chu & Chen Wang. (2015) Smoking cessation in Asians: focus on varenicline. Patient Preference and Adherence 9, pages 579-584.
Read now
Read now
Jacques Le Houezec & Henri-Jean Aubin. (2013) Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence. Expert Opinion on Pharmacotherapy 14:14, pages 1959-1967.
Read now
Read now
H Boudrez, J-P Hoengenaert, K Nackaerts, M Messig & M Metcalfe. (2013) PREDICTORS OF QUIT SUCCESS IN BELGIAN PARTICIPANTS OF A VARENICLINE OBSERVATIONAL SMOKING CESSATION STUDY. Acta Clinica Belgica 68:1, pages 37-42.
Read now
Read now
GladysN. Pachas, Corinne Cather, SarahI. Pratt, Bettina Hoeppner, Johanna Nino, SaraV. Carlini, EricD. Achtyes, Harry Lando, KimT. Mueser, NancyA. Rigotti, DonaldC. Goff & A.
Eden Evins. (2012) Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week Open-Label Trial. Journal of Dual Diagnosis 8:2, pages 117-125.
Read now
Read now
Nia Thompson, Niaman Nazir, Lisa Sanderson Cox, Babalola Faseru, Kathy Goggin, Jasjit S Ahluwalia & Nicole L Nollen. (2011) Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial. Patient Preference and Adherence 5, pages 475-482.
Read now
Read now
Jill M Williams, Michael B Steinberg, Marc L Steinberg, Kunal K Gandhi, Rajiv Ulpe & Jonathan Foulds. (2011) Varenicline for tobacco dependence: panacea or plight?. Expert Opinion on Pharmacotherapy 12:11, pages 1799-1812.
Read now
Read now
N Robson. (2011) Varenicline: a new pharmacotherapy for smoking cessation in primary care practice. South African Family Practice 53:3, pages 217-222.
Read now
Read now
Hedwig Boudrez, Christina Gratziou, Michael Messig & Michael Metcalfe. (2011) Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study. Current Medical Research and Opinion 27:4, pages 769-775.
Read now
Read now
José Juan Escobar-Chávez, Clara Luisa Domínguez-Delgado & Isabel Marlen Rodríguez-Cruz. (2011) Targeting nicotine addiction: the possibility of a therapeutic vaccine. Drug Design, Development and Therapy 5, pages 211-224.
Read now
Read now
Zheng-Xiong Xi. (2010) Preclinical pharmacology, efficacy, and safety of varenicline in smoking cessation and clinical utility in high risk patients. Drug, Healthcare and Patient Safety 2, pages 39-48.
Read now
Read now
Serena Tonstad & Hans Rollema. (2010) Varenicline in smoking cessation. Expert Review of Respiratory Medicine 4:3, pages 291-299.
Read now
Read now
Articles from other publishers (71)
Jonathan Livingstone-Banks, Thomas R Fanshawe, Kyla H Thomas, Annika Theodoulou, Anisa Hajizadeh, Lilian Hartman & Nicola Lindson. (2023) Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2023:6.
Crossref
Crossref
Jonathan Livingstone-Banks, Thomas R Fanshawe, Kyla H Thomas, Annika Theodoulou, Anisa Hajizadeh, Lilian Hartman & Nicola Lindson. (2023) Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2023:5.
Crossref
Crossref
Tierney A. Fisher & Frank T. Leone. 2023. Tobacco Dependence. Tobacco Dependence
75
91
.
Larry W. HawkJrJr, Stephen T. Tiffany, Craig R. Colder, Rebecca L. Ashare, Jennifer M. Wray, Rachel F. Tyndale, Thomas H. Brandon & Martin C. Mahoney. (2022) Effect of Extending the Duration of Prequit Treatment With Varenicline on Smoking Abstinence. JAMA Network Open 5:11, pages e2241731.
Crossref
Crossref
Stamatina Driva, Aliki Korkontzelou, Serena Tonstad, Nikolaos Tentolouris & Paraskevi Katsaounou. (2022) The Effect of Smoking Cessation on Body Weight and Other Metabolic Parameters with Focus on People with Type 2 Diabetes Mellitus. International Journal of Environmental Research and Public Health 19:20, pages 13222.
Crossref
Crossref
Kyla H. Thomas, Michael N. Dalili, José A. López‐López, Edna Keeney, David M. Phillippo, Marcus R. Munafò, Matt Stevenson, Deborah M. Caldwell & Nicky J. Welton. (2021) Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta‐analysis of randomized controlled trials. Addiction 117:4, pages 861-876.
Crossref
Crossref
Marjorie Erdmann, Bryan Edwards & Mopileola Tomi Adewumi. (2022) Effect of Electronic Portal Messaging With Embedded Asynchronous Care on Physician-Assisted Smoking Cessation Attempts. JAMA Network Open 5:2, pages e220348.
Crossref
Crossref
Christian C. Jacob & Thomas Polak. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2603
2633
.
Ju Sam Hwang & Cheol Min Lee. (2021) Recent Updates of Pharmacotherapy for Smoking Cessation. Korean Journal of Family Practice 11:6, pages 403-414.
Crossref
Crossref
Jamie Hartmann-Boyce, Annika Theodoulou, Amanda Farley, Peter Hajek, Deborah Lycett, Laura L Jones, Laura Kudlek, Laura Heath, Anisa Hajizadeh, Marika Schenkels & Paul Aveyard. (2021) Interventions for preventing weight gain after smoking cessation. Cochrane Database of Systematic Reviews 2021:10.
Crossref
Crossref
Kyla H Thomas, Michael N Dalili, José A López-López, Edna Keeney, David Phillippo, Marcus R Munafò, Matt Stevenson, Deborah M Caldwell & Nicky J Welton. (2021) Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment 25:59, pages 1-224.
Crossref
Crossref
Archana Mishra, Rituparna Maiti, Biswa Ranjan Mishra & Monalisa Jena. (2021) Comparative efficacy and safety of pharmacological interventions for smoking cessation in healthy adults: A network meta-analysis. Pharmacological Research 166, pages 105478.
Crossref
Crossref
Evangelia Liakoni & Neal L. Benowitz. 2021. Supporting Tobacco Cessation. Supporting Tobacco Cessation
97
117
.
Annie R. Peng, Walter Swardfager, Neal L. Benowitz, Jasjit S. Ahluwalia, Caryn Lerman, Nicole L. Nollen & Rachel F. Tyndale. (2019) Impact of early nausea on varenicline adherence and smoking cessation. Addiction 115:1, pages 134-144.
Crossref
Crossref
Christian Jacob & Thomas Polak. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
32
.
Vernon Garcia-Rivas, Jean-François Fiancette, Nazzareno Cannella, Maria Carbo-Gas, Prisca Renault, Jessica Tostain & Véronique Deroche-Gamonet. (2019) Varenicline Targets the Reinforcing-Enhancing Effect of Nicotine on Its Associated Salient Cue During Nicotine Self-administration in the Rat. Frontiers in Behavioral Neuroscience 13.
Crossref
Crossref
Sarah E. Jackson, Jennifer A. McGowan, Harveen Kaur Ubhi, Hannah Proudfoot, Lion Shahab, Jamie Brown & Robert West. (2019) Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation. Addiction 114:5, pages 787-797.
Crossref
Crossref
Anil Batra, Melanie Düerkop, Marcus Gertzen, Andreas Jähne, Stephan Mühlig & Tobias Rüther. 2019. Suchtmedizin. Suchtmedizin
237
258
.
Elena V. Radchenko, Olga A. Sykhovskaya, Timofey L. Galankin, Aleksei S. Kolbin & Maria A. Smirnova. (2018) Network meta-analysis: a comparison of effectiveness and safety of partial agonists of nicotinic acetylcholine receptors varenicline and cytisine for smoking cessation. Reviews on Clinical Pharmacology and Drug Therapy 16:4, pages 19-32.
Crossref
Crossref
Tam RamseyEric GuoPeter F. Svider, Hosheng LinSara SyedaS. Naweed RazaAndrew M. Fribley. (2018) Laryngeal cancer: Global socioeconomic trends in disease burden and smoking habits. The Laryngoscope 128:9, pages 2039-2053.
Crossref
Crossref
Rüyal Tan, Funda Bölükbaşi Hatip, Öznur Açikalin, Atsushi Yamauchi, Yasufumi Kataoka & Izzettin Hatip-Al-Khatib. (2018) Effect of varenicline on behavioral deficits in a rat model of Parkinson’s disease induced by unilateral 6-hydroxydopamine lesion of substantia nigra. Behavioural Pharmacology 29:4, pages 327-335.
Crossref
Crossref
Yanxin Sun, Wenhou Duan, Xin Meng, Huijie Li & Chongqi Jia. (2018) Varenicline is associated with a modest limitation in weight gain in smokers after smoking cessation: a meta-analysis. Journal of Public Health 40:2, pages e126-e132.
Crossref
Crossref
J. Abdul-Kader, G. Airagnes, S. D’almeida, F. Limosin & A.-L. Le Faou. (2018) Les outils du sevrage tabagique en 2018. Revue de Pneumologie Clinique 74:3, pages 160-169.
Crossref
Crossref
Aaron D. Drovandi, Peta-Ann Teague, Beverley D. Glass & Bunmi Malau-Aduli. (2017) A Systematic Review Investigating the Impact of Modified Varenicline Regimens on Smoking Cessation. Journal of Smoking Cessation 13:1, pages 44-54.
Crossref
Crossref
Thaniya Klinsophon, Premtip Thaveeratitham, Ekalak Sitthipornvorakul & Prawit Janwantanakul. (2017) Effect of exercise type on smoking cessation: a meta-analysis of randomized controlled trials. BMC Research Notes 10:1.
Crossref
Crossref
Rae A. Littlewood, Eric D. Claus, Claire E. Wilcox, Jessica Mickey, Pamela B. Arenella, Angela D. Bryan & Kent E. Hutchison. (2017) Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo. Psychopharmacology 234:23-24, pages 3417-3429.
Crossref
Crossref
Natalia Fouz-Rosón, Teodoro Montemayor-Rubio, Virginia Almadana-Pacheco, Soledad Montserrat-García, Ana Paulina Gómez-Bastero, Concepción Romero-Muñoz & Juan Polo-Padillo. (2017) Effect of 0.5 mg versus 1 mg varenicline for smoking cessation: a randomized controlled trial. Addiction 112:9, pages 1610-1619.
Crossref
Crossref
Sarah B. Windle, Kristian B. Filion, Joseph G. Mancini, Lauren Adye-White, Lawrence Joseph, Genevieve C. Gore, Bettina Habib, Roland Grad, Louise Pilote & Mark J. Eisenberg. (2016) Combination Therapies for Smoking Cessation. American Journal of Preventive Medicine 51:6, pages 1060-1071.
Crossref
Crossref
Qi Wu, Simon Gilbody, Emily Peckham, Sally Brabyn & Steve Parrott. (2016) Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis. Addiction 111:9, pages 1554-1567.
Crossref
Crossref
Philip H. Smith, Andrea H. Weinberger, Ju Zhang, Erin Emme, Carolyn M. Mazure & Sherry A. McKee. (2016) Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis. Nicotine & Tobacco Research, pages ntw144.
Crossref
Crossref
Kate Cahill, Nicola Lindson-Hawley, Kyla H Thomas, Thomas R Fanshawe & Tim Lancaster. (2016) Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Sherry A. McKee, Philip H. Smith, Mira Kaufman, Carolyn M. Mazure & Andrea H. Weinberger. (2016) Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis. Nicotine & Tobacco Research 18:5, pages 1002-1011.
Crossref
Crossref
Lee H. Sterling, Sarah B. Windle, Kristian B. Filion, Lahoud Touma & Mark J. Eisenberg. (2016) Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association 5:2.
Crossref
Crossref
A. Batra, K. U. Petersen, E. Hoch, K. Mann, C. Kröger, C. Schweizer, A. Jähne, T. Rüther, N. Thürauf & S. Mühlig. (2015) Psycho- und Pharmakotherapie bei schädlichem Tabakgebrauch und -abhängigkeitPsychotherapy and pharmacotherapy for harmful tobacco use and tobacco dependency. Der Nervenarzt 87:1, pages 35-45.
Crossref
Crossref
Shade A. Agboola, Tim Coleman, Ann McNeill & Jo Leonardi-Bee. (2015) Abstinence and relapse among smokers who use varenicline in a quit attempt-a pooled analysis of randomized controlled trials. Addiction 110:7, pages 1182-1193.
Crossref
Crossref
D Gonzales, P Hajek, L Pliamm, K Nackaerts, L-J Tseng, T D McRae & J Treadow. (2014) Retreatment With Varenicline for Smoking Cessation in Smokers Who Have Previously Taken Varenicline: A Randomized, Placebo-Controlled Trial. Clinical Pharmacology & Therapeutics 96:3, pages 390-396.
Crossref
Crossref
Henri-Jean Aubin, Amandine Luquiens & Ivan Berlin. (2014) Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. British Journal of Clinical Pharmacology 77:2, pages 324-336.
Crossref
Crossref
Edward J. MillsKristian ThorlundShawn EapenPing WuJudith J. Prochaska. (2014) Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies. Circulation 129:1, pages 28-41.
Crossref
Crossref
Christina E. Ciaccio & Deborah Gentile. (2013) Effects of Tobacco Smoke Exposure in Childhood on Atopic Diseases. Current Allergy and Asthma Reports 13:6, pages 687-692.
Crossref
Crossref
J. Foulds, C. Russ, C.-R. Yu, K. H. Zou, A. Galaznik, M. Franzon, A. Berg & J. R. Hughes. (2013) Effect of Varenicline on Individual Nicotine Withdrawal Symptoms: A Combined Analysis of Eight Randomized, Placebo-Controlled Trials. Nicotine & Tobacco Research 15:11, pages 1849-1857.
Crossref
Crossref
James H. Ware, George W. Vetrovec, Alan B. Miller, Andrew Van Tosh, Michael Gaffney, Carla Yunis, Carmen Arteaga & Jeffrey S. Borer. (2013) Cardiovascular Safety of Varenicline. American Journal of Therapeutics 20:3, pages 235-246.
Crossref
Crossref
K. Fagerstrom, C. Russ, C.-R. Yu, C. Yunis & J. Foulds. (2012) The Fagerstrom Test for Nicotine Dependence as a Predictor of Smoking Abstinence: A Pooled Analysis of Varenicline Clinical Trial Data. Nicotine & Tobacco Research 14:12, pages 1467-1473.
Crossref
Crossref
Yubei Huang, Weiqin Li, Li Yang, Yuan Jiang & Yangfeng Wu. (2012) Long-term efficacy and safety of varenicline for smoking cessation: a systematic review and meta-analysis of randomized controlled trials. Journal of Public Health 20:4, pages 355-365.
Crossref
Crossref
Ranjit K. Dhelaria, Jennifer Friderici, Kelly Wu, Ella Gupta, Cyrus Khan & Michael B. Rothberg. (2012) Effectiveness of varenicline for smoking cessation at 2 urban academic health centers. European Journal of Internal Medicine 23:5, pages 461-464.
Crossref
Crossref
Kate Cahill, Lindsay F Stead & Tim Lancaster. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Amanda C Farley, Peter Hajek, Deborah Lycett & Paul Aveyard. (2012) Interventions for preventing weight gain after smoking cessation. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Christina Gratziou, Konstantinos Gourgoulianis, Paraskevi Pataka, Georgia D Sykara, Michael Messig & Sunil Raju. (2012) Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study. Tobacco Induced Diseases 10:1, pages 1.
Crossref
Crossref
Lawrence K Leung, Francis M Patafio & Walter W Rosser. (2011) Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis. BMC Clinical Pharmacology 11:1.
Crossref
Crossref
Susan Albrecht, Karen Kelly‐Thomas, Jason W. Osborne & Semhar Ogbagaber. (2011) The SUCCESS Program for Smoking Cessation for Pregnant Women. Journal of Obstetric, Gynecologic & Neonatal Nursing 40:5, pages 520-531.
Crossref
Crossref
Dahlia Garza, Michael Murphy, Li-Jung Tseng, Henry J. Riordan & Anjan Chatterjee. (2011) A Double-Blind Randomized Placebo-Controlled Pilot Study of Neuropsychiatric Adverse Events in Abstinent Smokers Treated with Varenicline or Placebo. Biological Psychiatry 69:11, pages 1075-1082.
Crossref
Crossref
Harold S Javitz, Susan M Zbikowski, Mona Deprey, Timothy A McAfee, Jennifer B McClure, Julie Richards, Sheryl L Catz, Lisa M Jack & Gary E Swan. (2010) Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation. Translational Behavioral Medicine 1:1, pages 182-190.
Crossref
Crossref
Kate Cahill, Lindsay F Stead & Tim Lancaster. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
RAOUL A. WALSH. (2011) AUSTRALIA'S EXPERIENCE WITH VARENICLINE: USAGE, COSTS AND ADVERSE REACTIONS. Addiction 106:2, pages 451-452.
Crossref
Crossref
Kate Cahill, Lindsay F Stead & Tim Lancaster. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
J. Taylor Hays & Jon O. Ebbert. (2010) Adverse Effects and Tolerability of Medications for the Treatment of Tobacco Use and Dependence. Drugs 70:18, pages 2357-2372.
Crossref
Crossref
Aryeh I. Herman & Mehmet Sofuoglu. (2010) Comparison of Available Treatments for Tobacco Addiction. Current Psychiatry Reports 12:5, pages 433-440.
Crossref
Crossref
Carlos A. Jiménez-Ruiz & Karl O. Fagerström. (2010) Advances in Smoking Cessation. Clinical Pulmonary Medicine 17:3, pages 140-145.
Crossref
Crossref
Gary E. Swan, Jennifer B. McClure, Lisa M. Jack, Susan M. Zbikowski, Harold S. Javitz, Sheryl L. Catz, Mona Deprey, Julie Richards & Timothy A. McAfee. (2010) Behavioral Counseling and Varenicline Treatment for Smoking Cessation. American Journal of Preventive Medicine 38:5, pages 482-490.
Crossref
Crossref
Serena Tonstad, Simon Davies, Martina Flammer, Cristina Russ & John Hughes. (2010) Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline. Drug Safety 33:4, pages 289-301.
Crossref
Crossref
Gillian M. Keating & Katherine A. Lyseng-Williamson. (2010) Varenicline. PharmacoEconomics 28:3, pages 231-254.
Crossref
Crossref
Serena TonstadCharl Els. (2010) Varenicline: Smoking Cessation in Patients with Medical and Psychiatric Comorbidity. Clinical Medicine Insights: Therapeutics 2, pages CMT.S4012.
Crossref
Crossref
Patrick Dupont, Claudine Gillet, Martine Guerin, Sophie Kalamarides, Élisabeth Larinier, Claire Meignan, Aline Moreau, Claude Guillaumin & Jean Perriot. (2010) Tolérance de la varénicline en pratique courante. La Presse Médicale 39:1, pages e17-e24.
Crossref
Crossref
Kimberly S. Johnson & Michael S. Tankersley. (2009) Smoking cessation toolbox for allergists. Annals of Allergy, Asthma & Immunology 103:4, pages 271-279.
Crossref
Crossref
Peter Hajek, Philip Tønnesen, Carmen Arteaga, Cristina Russ & Serena Tonstad. (2009) Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction 104:9, pages 1597-1602.
Crossref
Crossref
Frank T. Leone & Sarah Evers-Casey. (2009) Behavioral Interventions in Tobacco Dependence. Primary Care: Clinics in Office Practice 36:3, pages 489-507.
Crossref
Crossref
J. Taylor Hays, Jon O. Ebbert & Amit Sood. (2009) Treating Tobacco Dependence in Light of the 2008 US Department of Health and Human Services Clinical Practice Guideline. Mayo Clinic Proceedings 84:8, pages 730-736.
Crossref
Crossref
Carlos Jiménez-Ruiz, Ivan Berlin & Thomas Hering. (2009) Varenicline. Drugs 69:10, pages 1319-1338.
Crossref
Crossref
Gina Daubney Garrison & Sara E. Dugan. (2009) Varenicline: A first-line treatment option for smoking cessation. Clinical Therapeutics 31:3, pages 463-491.
Crossref
Crossref
Kate Cahill, Lindsay Stead & Tim Lancaster. (2009) A Preliminary Benefit-Risk Assessment of Varenicline in Smoking Cessation. Drug Safety 32:2, pages 119-135.
Crossref
Crossref
T. Hering. (2008) Moderne medikamentöse Unterstützung der TabakentwöhnungModern medical support for smoking cessation. Der Internist 50:1, pages 95-100.
Crossref
Crossref
G. Peiffer. (2008) Actualités des pharmacothérapies du tabagisme et du cannabisme. Revue des Maladies Respiratoires 25:10, pages 1356-1357.
Crossref
Crossref